Downregulation of either CD24 or Siglec-10, as well as blockade of the CD24-Siglec-10 axis via monoclonal antibodies, enhanced the phagocytosis of CD24-expressing ovarian cancer cells and resulted in a macrophage-dependent reduction in tumor growth in vivo and increased survival [113]. This evidence concerns the gene CD24 and neoplasm.